Survival analysis after hematopoietic stem cell transplantation in the treatment of hematological malignancies
- Author:
Lan XU
1
Author Information
1. Department of Hematology
- Publication Type:Journal Article
- Keywords:
Hematologic neoplasms;
Hematopoietic stem cell transplantation;
Leukemia;
Lymphoma, non-Hodgkin;
Prognosis
- From:
Tumor
2007;27(4):312-315
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinical efficacy of hematopoietic stem cell transplantation (HSCT) in the treatment of hematological malignancies and compare the survival rate between the patients who were at different stages of disease and received different preconditioning regimen. Methods: Of the 38 patients, 25 patients received allogeneic transplantation and 13 patients underwent autogeneic transplantation. According to the phases of disease the patients were divided into two groups, standard-risk group (26 cases) and high-risk group (12 cases). The study was terminated by the death of the patients or after last follow-up. The overall survival (OS), transplant-related mortality (TRM), and the relapse rate were analyzed. Results: The 6-year expected OS, TRM, and the relapse rate were (50.36 ± 9.36)%, (21.47 ± 8.17)%, and (35.93 ± 9.89)%, respectively. The 6-year OS was(60.10 ± 10.39)% in standard-risk group. The 9-month OS was significantly higher in standard-risk group than that in high-risk group [(78.59 ± 21.41)% vs (28.86 ± 16.58)%; P=0.0118)]. The expected 6-year relapse rate of standard-risk group was significantly lower than that in high-risk group [(26.2 ± 10.16)% vs (74.07 ± 21.67)%, P=0.0062]. There was no significant difference in the 6-year OS between the patients who received allogeneic and autogeneic HSCT [(54.52 ± 10.87)% vs (40.00 ± 17.38)%, P=0.70]. The expected 6-year OS of patients who received total body irradiation (TBI) was superior than those who did not receive TBI preconditioning [(57.10 ± 10.44)% vs (22.86 ± 18.72)%, P=0.029]. Conclusion: HSCT is an effective method for the treatment of hematological malignancies. The long survival and relapse rate are significantly influenced by the stage of disease and preconditioning regimen.
